Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer

Cancer Prevention Research

Volumn 8, Issue 2, 2015, Pages 165-173

  Xie, Zijun ^a,b   Yin, Xiaoyu ^b   Gong, Bo ^c   Nie, Wenjing ^c   Wu, Bin ^b   Zhang, Xuchao ^a   Huang, Jian ^a   Zhang, Pingyou ^a   Zhou, Zhiwei ^d   Li, Zijun ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; MICRORNA; MICRORNA 1273G; MICRORNA 3679; MICRORNA 3940; MICRORNA 4327; MICRORNA 4442; MICRORNA 4665; MICRORNA 940; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN3679 MICRORNA, HUMAN; MIRN940 MICRORNA, HUMAN;

ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SALIVA; SALIVA ANALYSIS; UPREGULATION; AREA UNDER THE CURVE; CHEMISTRY; DNA MICROARRAY; GENETICS; PANCREATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AREA UNDER CURVE; BIOMARKERS, TUMOR; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SALIVA; SENSITIVITY AND SPECIFICITY;

EID: 84961290289     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0192     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, CA Cancer J Clin 2008;58:71-96.
2. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002;16:37-52.
3. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchle MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-94.
4. Wu E, Zhou S, Bhat K, Ma Q. CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol 2013;11:53-5.
5. Lee YH, Wong DT. Saliva: an emerging biofluid for early detection of diseases. Am J Dent 2009;22:241-8.
6. Li Y, St JM, Zhou X, Kim Y, Sinha U, Jordan RC, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004;10:8442-50.
7. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008;14:6246-52.
8. Brinkmann O, Spielmann N, Wong DT. Salivary diagnostics: moving to the next level. Dent Today 2012;31:56-7.
9. Brooks MN, Wang J, Li Y, Zhang R, Elashoff D, Wong DT, et al. Salivary protein factors are elevated in breast cancer patients. Mol Med Rep 2008;1:375-8.
10. Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, et al. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS ONE 2010;5:e15573.
11. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci 2012;69:3341-50.
12. Lee YH, Kim JH, Zhou H, Kim BW, Wong DT. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma. J Mol Med 2012;90:427-34.
13. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 2007;56:3588-600.
14. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific pro files. Metabolomics 2010;6:78-95.
15. Wong DT. Salivaomics. J Am Dent Assoc 2012;143:19S-24S.
16. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138:949-57.
17. Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin DB, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012;61:582-8.
18. Croce C. Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J 2012;18:213-4.
19. Wan C, Shen Y, Yang T, Wang T, Chen L, Wen F, et al. Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci 2012;8:749-55.
20. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-7.
21. Matse JH, Yoshizawa J, Wang X, Elashoff D, Bolscher JG, Veerman EC, et al. Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors. Clin Cancer Res 2013;19:3032-8.
22. Alevizos I, Alexander S, Turner RJ, Henson BS, Kastratovic DA, Abemayor E, et al. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum 2011;63:535-44.
23. Xie ZJ, Chen G, Zhang XC, Li DF, Huang J, Li ZJ, et al. Saliva supernatant miR-21: a novel potential biomarker for esophageal cancer detection. Asian Pac J Cancer Prev 2012;13:6145-9.
24. Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, et al. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS ONE 2013;8:e57502.
25. Margare T, Steven JC, Aaron RS, Edgar BJ, Ai BB, Ephraim SC, et al. National Comprehensive Cancer Network: Practice Guidelines in Oncologyv.2.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2011. p. 17.
26. th ed). New York, NY: Springer; 2010. p. 74-6.
27. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, et al. Exosomes from human saliva as a source of microRNA biomarkers. Oral Di 2010;16:34-8.
28. Patel RS, Jakymiw A, Yao B, Pauley BA, Carcamo WC, Katz J, et al. High resolution of microRNA signatures in human whole saliva. Arch Oral Biol 2011;56:1506-13.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
30. Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol 2011;2:88-100.
31. Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, et al. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol 2012;33:799-807.
32. Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994;9:703-6.
33. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6.
34. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
35. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-7.
36. Miller CS, Foley JD, Bailey AL, Campell CL, Humphries RL, Christodoulides N, et al. Current developments in salivary diagnostics. Biomark Med 2010;4:171-89.
37. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, et al. Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS ONE 2009;4:e5875.